Sign in
WithdrawnPhase 2

Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)

Key facts

Who runs it
Valo Health, Inc.
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Sept 2022
Ended
Nov 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • OPL-0301 Dose 1
  • OPL-0301 Dose 2
  • Placebo
Record updated
21 February 2023
Why it stopped
Withdrawn based on business decision, no participants enrolled

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Are male or female between 18 and 90 years of age, inclusive, at the time of signing the informed consent
  • Are hospitalized with acute ST-Elevated Myocardial Infarction (STEMI), defined based on American Heart Association (AHA)/American College of Cardiology (ACC) criteria
  • Have cardiac troponin-I (cTnI), cardiac troponin-T (cTnT) levels ≥10x upper limit of normal (ULN) at least once during the index event of myocardial infarction

Who cannot take part

  • Previous history of documented myocardial infarction
  • Previous history of percutaneous coronary intervention (PCI) within 6 months or coronary artery bypass graft surgery (CABG) or valvular heart surgery at any time prior to screening
  • Previous history of decompensated heart failure
  • Previous history of documented specific cardiomyopathy (including but not limited to hypertrophic cardiomyopathy (HCM), amyloid, sarcoid, etc.)
  • Previous history of documented arrhythmias
  • Are being treated with Sphingosine-1 Phosphate (S1P) modulators (fingolimod, siponimod, ozanimod, ponesimod)
  • Previous history of documented chronic left ventricular dysfunction with ejection fraction (EF) < 50%

About the trial

What the trial wants to find out

Study OPL-0301-201 is intended to generate efficacy and safety data of OPL-0301 in participants with post-myocardial infarction (MI) left ventricular dysfunction (LVD)

The 3 groups in the trial

  • OPL-0301 Dose 1Treatment being tested

    Participants are randomized to OPL-0301 Dose 1 administered once daily for 90 days

  • OPL-0301 Dose 2Treatment being tested

    Participants are randomized to OPL-0301 Dose 2 administered once daily for 90 days

  • PlaceboPlacebo, for comparison

    Participants are randomized to matching placebo administered once daily for 90 days

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-arm, Parallel-group, Adaptive Study to Investigate the Efficacy and Safety of OPL-0301 in Patients With Post-myocardial Infarction Left Ventricular Dysfunction (RESTORE)
Record updated
21 February 2023